主要收入构成
报告期:2023-12-31
主营产品构成(百万) |
名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
儿童用药 |
11.55% |
188.17 |
24.74% |
65.67 |
65.10% |
0.97% |
妇科疾病用药 |
5.67% |
92.37 |
-15.21% |
19.16 |
79.26% |
-0.76% |
骨骼肌肉系统用药 |
22.04% |
358.93 |
-2.34% |
52.38 |
85.41% |
-0.11% |
呼吸系统用药 |
11.03% |
179.61 |
27.96% |
49.48 |
72.45% |
0.88% |
抗感染用药 |
5.03% |
81.85 |
-14.98% |
52.95 |
35.31% |
-2.48% |
其他 |
17.44% |
283.97 |
-35.14% |
145.28 |
48.84% |
10.19% |
其他(补充) |
3.63% |
59.09 |
43.19% |
34.51 |
41.61% |
-32.62% |
心脑血管疾病用药 |
23.61% |
384.55 |
-14.34% |
100.10 |
73.97% |
-8.63% |
总计 |
1628.54 |
行业收入构成(百万) |
名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
其他 |
1.45% |
23.63 |
45.62% |
20.06 |
15.11% |
-26.03% |
其他(补充) |
3.63% |
59.09 |
43.19% |
34.51 |
41.61% |
-32.62% |
医疗业务 |
2.54% |
41.39 |
-80.90% |
34.55 |
16.52% |
-11.05% |
医药商业 |
4.03% |
65.69 |
-12.58% |
45.72 |
30.41% |
11.90% |
医药制造 |
88.35% |
1438.74 |
-0.27% |
384.71 |
73.26% |
-2.62% |
总计 |
1628.54 |
地区收入构成(百万) |
名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
湖南 |
17.72% |
288.65 |
-38.99% |
84.02 |
70.89% |
17.43% |
华北地区 |
12.79% |
208.27 |
-19.35% |
53.43 |
74.35% |
-3.89% |
华东地区 |
18.40% |
299.63 |
-1.98% |
87.69 |
70.73% |
-2.04% |
华南地区 |
9.93% |
161.68 |
42.19% |
57.33 |
64.54% |
-5.95% |
华中地区 |
17.22% |
280.43 |
5.76% |
117.99 |
57.92% |
-4.45% |
其他(补充) |
3.63% |
59.09 |
43.19% |
34.51 |
41.61% |
-32.62% |
西北地区 |
4.80% |
78.11 |
-2.25% |
18.75 |
76.00% |
-1.75% |
西南地区 |
15.52% |
252.68 |
-0.90% |
65.82 |
73.95% |
-0.58% |
总计 |
1628.54 |